drugset / Trial / NCT05142475
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Phase 0
Recruiting
50 enrolled
Shanghai Juncell Therapeutics
Shanghai 10th People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Timeline
- Start
- 2021-11-19
- Primary completion
- 2026-12-20
- Completion
- 2027-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | 5e+10 cells | Intravenous |